These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36866838)

  • 1. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
    Lesokhin A; LeBlanc R; Dimopoulos MA; Capra M; Carlo-Stella C; Karlin L; Castilloux JF; Forsberg P; Parmar G; Tosikyan A; Pour L; Ribrag V; Ribolla R; Abdallah AO; Le Roux N; Dong L; van de Velde H; Mayrargue L; Lépine L; Macé S; Moreau P
    Cancer Med; 2023 May; 12(9):10254-10266. PubMed ID: 36866838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
    Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
    Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
    Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
    Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
    Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
    Shimazu Y; Kanda J; Onda Y; Fuchida SI; Ohta K; Shimura Y; Kosugi S; Yamamura R; Matsuda M; Hanamoto H; Adachi Y; Anzai N; Hotta M; Fukushima K; Yagi H; Yoshihara S; Tanaka Y; Takakuwa T; Tanaka H; Shibayama H; Uoshima N; Hosen N; Ito T; Shimazaki C; Matsumura I; Kuroda J; Takaori-Kondo A; Hino M
    Cancer Immunol Immunother; 2024 May; 73(7):135. PubMed ID: 38758239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
    Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
    Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
    Sunami K; Ikeda T; Huang SY; Wang MC; Koh Y; Min CK; Yeh SP; Matsumoto M; Uchiyama M; Iyama S; Shimazaki C; Lee JH; Kim K; Kaneko H; Kim JS; Lin TL; Campana F; Tada K; Iida S; Suzuki K;
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e751-e761. PubMed ID: 35641409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
    Shah B; Gray J; Abraham I; Chang M
    J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
    Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
    Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.